What is Zylox-Tonbridge Medical Technology Co Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Zylox-Tonbridge Medical Technology Co Sloan Ratio % Chart
Zylox-Tonbridge Medical Technology Co Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
Sloan Ratio %
37.21
45.84
38.32
2.24
0.86
Zylox-Tonbridge Medical Technology Co Semi-Annual Data
Competitive Comparison of Zylox-Tonbridge Medical Technology Co's Sloan Ratio %
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Sloan Ratio % falls into.
Zylox-Tonbridge Medical Technology Co Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2024, Zylox-Tonbridge Medical Technology Co has a Sloan Ratio of 22.64%, indicating there is a warning stage of accrual build up.
Zylox-Tonbridge Medical Technology Co Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Zylox-Tonbridge Medical Technology Co Business Description
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02190 has been successfully added to your 